Inside STAT: Bispecific antibodies are the next new thing in cancer therapy

ILLUSTRATION OF A BITE, AMGEN'S BISPECIFIC ANTIBODIES. (AMGEN)

It’s been less than two years since the approval of the first CAR-T treatment  — but pharma companies and biotechs are already talking about the next generation of cancer therapy. Roughly two dozen companies are developing treatments called bispecific antibodies designed to train the immune system to kill tumor cells like CAR-T. But unlike CAR-T therapies — which are difficult to manufacture — the bispecific antibodies can start being infused almost as fast as an oncologist writes a prescription. Sharon Begley has the story here for STAT Plus subscribers — read here.